Indivior PLC (INDV.L)

1.421,00 -24,00 (-1,66%) A partir del 01:22PM BST. Mercado abierto.

Indivior PLC

10710 Midlothian Turnpike
Suite 125
North Chesterfield, VA 23235
United States
804 379 1090
https://www.indivior.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1000

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Mark Crossley	CEO & Executive Director	1,84M	N/A	N/A
Mr. Ryan Preblick	CFO & Executive Director	893,85k	N/A	N/A
Dr. Christian Heidbreder	Chief Scientific Officer	N/A	N/A	N/A
Mr. Jason Thompson	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Cynthia Cetani	Chief Integrity & Compliance Officer	N/A	N/A	N/A
Mr. Jeffrey W. Burris	Chief Legal Officer	N/A	N/A	1972
Mr. Jon Fogle	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Richard Simkin	Chief Commercial Officer	N/A	N/A	N/A
Mr. Hillel West	Chief Manufacturing & Supply Officer	N/A	N/A	N/A
Mr. Vishal Kalia	SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en GBp.

Descripción

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Gobierno corporativo

El ISS Governance QualityScore de Indivior PLC, a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 10; Tablero: 5; Derechos de los accionistas: 1; Compensación: 6.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.